4D Molecular Therapeutics, Inc. (FDMT) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for 4D Molecular Therapeutics, Inc., with annual and quarterly history.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| P/E Ratio | -3.10x | -1.87x | -7.86x | -6.68x | -8.53x | -19.51x |
| P/B Ratio | 0.86x | 0.59x | 2.58x | 3.11x | 1.91x | 4.31x |
| P/S Ratio | 5.10x | 8120.72x | 38.26x | 229.63x | 33.73x | 81.25x |
| Profitability | ||||||
| Gross Margin | 91.1% | 100.0% | -368.5% | -2464.8% | -240.2% | -289.6% |
| Operating Margin | -187.2% | -507678.4% | -544.6% | -3516.5% | -395.5% | -416.3% |
| Net Margin | -164.4% | -434778.4% | -486.6% | -3435.4% | -395.4% | -416.5% |
| EBITDA Margin | -178.3% | -489556.8% | -524.4% | -3439.7% | -387.0% | -405.7% |
| Liquidity | ||||||
| Current Ratio | 9.39x | 14.92x | 15.65x | 14.02x | 15.69x | 16.88x |
| Quick Ratio | 9.39x | 14.92x | 15.65x | 14.02x | 15.69x | 16.88x |
| Leverage | ||||||
| Debt/Equity | 0.04x | 0.05x | 0.05x | 0.07x | 0.05x | 0.00x |
YoY = year-over-year change. Source: FMP..